BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schrag A, Sauerbier A, Chaudhuri KR. New clinical trials for nonmotor manifestations of Parkinson's disease. Mov Disord 2015;30:1490-504. [PMID: 26371623 DOI: 10.1002/mds.26415] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 9.7] [Reference Citation Analysis]
Number Citing Articles
1 Deeb W, Nozile-Firth K, Okun MS. Parkinson's disease: Diagnosis and appreciation of comorbidities. Handb Clin Neurol 2019;167:257-77. [PMID: 31753136 DOI: 10.1016/B978-0-12-804766-8.00014-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Hogg E, Wertheimer J, Graner S, Tagliati M. Deep Brain Stimulation and Nonmotor Symptoms. Nonmotor Parkinson’s: The Hidden Face - Management and the Hidden Face of Related Disorders. Elsevier; 2017. pp. 1045-89. [DOI: 10.1016/bs.irn.2017.05.022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
3 Bruno V, Freitas ME, Mancini D, Lui JP, Miyasaki J, Fox SH. Botulinum Toxin Type A for Pain in Advanced Parkinson’s Disease. Can J Neurol Sci 2018;45:23-9. [DOI: 10.1017/cjn.2017.245] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
4 Charles KA, Naudet F, Bouali-Benazzouz R, Landry M, De Deurwaerdère P, Fossat P, Benazzouz A. Alteration of nociceptive integration in the spinal cord of a rat model of Parkinson's disease. Mov Disord 2018;33:1010-5. [PMID: 29774960 DOI: 10.1002/mds.27377] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
5 Titova N, Chaudhuri KR. Palliative Care and Nonmotor Symptoms in Parkinson's Disease and Parkinsonism. Nonmotor Parkinson’s: The Hidden Face - Management and the Hidden Face of Related Disorders. Elsevier; 2017. pp. 1239-55. [DOI: 10.1016/bs.irn.2017.05.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
6 Chaudhuri KR, Bhidayasiri R, van Laar T. Unmet needs in Parkinson's disease: New horizons in a changing landscape. Parkinsonism Relat Disord 2016;33 Suppl 1:S2-8. [PMID: 27932224 DOI: 10.1016/j.parkreldis.2016.11.018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
7 Md S, Bhattmisra SK, Zeeshan F, Shahzad N, Mujtaba MA, Srikanth Meka V, Radhakrishnan A, Kesharwani P, Baboota S, Ali J. Nano-carrier enabled drug delivery systems for nose to brain targeting for the treatment of neurodegenerative disorders. Journal of Drug Delivery Science and Technology 2018;43:295-310. [DOI: 10.1016/j.jddst.2017.09.022] [Cited by in Crossref: 48] [Cited by in F6Publishing: 30] [Article Influence: 12.0] [Reference Citation Analysis]
8 Fabbri M, Coelho M, Guedes LC, Chendo I, Sousa C, Rosa MM, Abreu D, Costa N, Godinho C, Antonini A, Ferreira JJ. Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test. Parkinsonism Relat Disord 2017;39:37-43. [PMID: 28389156 DOI: 10.1016/j.parkreldis.2017.02.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
9 Sauerbier A, Rosa-Grilo M, Qamar MA, Chaudhuri KR. Nonmotor Subtyping in Parkinson's Disease. Int Rev Neurobiol 2017;133:447-78. [PMID: 28802928 DOI: 10.1016/bs.irn.2017.05.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
10 Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag A, Lang AE. Parkinson disease. Nat Rev Dis Primers 2017;3. [DOI: 10.1038/nrdp.2017.13] [Cited by in Crossref: 1345] [Cited by in F6Publishing: 1142] [Article Influence: 269.0] [Reference Citation Analysis]
11 Magrinelli F, Picelli A, Tocco P, Federico A, Roncari L, Smania N, Zanette G, Tamburin S. Pathophysiology of Motor Dysfunction in Parkinson's Disease as the Rationale for Drug Treatment and Rehabilitation. Parkinsons Dis 2016;2016:9832839. [PMID: 27366343 DOI: 10.1155/2016/9832839] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 10.7] [Reference Citation Analysis]
12 Titova N, Padmakumar C, Lewis SJG, Chaudhuri KR. Parkinson's: a syndrome rather than a disease? J Neural Transm (Vienna) 2017;124:907-14. [PMID: 28028643 DOI: 10.1007/s00702-016-1667-6] [Cited by in Crossref: 92] [Cited by in F6Publishing: 79] [Article Influence: 15.3] [Reference Citation Analysis]
13 Santangelo G, D'Iorio A, Maggi G, Cuoco S, Pellecchia MT, Amboni M, Barone P, Vitale C. Cognitive correlates of "pure apathy" in Parkinson's disease. Parkinsonism Relat Disord 2018;53:101-4. [PMID: 29706433 DOI: 10.1016/j.parkreldis.2018.04.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
14 Anderson C, Sheppard D, Dorval AD. Parkinsonism and subthalamic deep brain stimulation dysregulate behavioral motivation in a rodent model. Brain Res 2020;1736:146776. [PMID: 32171706 DOI: 10.1016/j.brainres.2020.146776] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
15 Titova N, Qamar MA, Chaudhuri KR. The Nonmotor Features of Parkinson's Disease. Int Rev Neurobiol 2017;132:33-54. [PMID: 28554413 DOI: 10.1016/bs.irn.2017.02.016] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 7.2] [Reference Citation Analysis]
16 Franke C, Storch A. Nonmotor Fluctuations in Parkinson's Disease. Nonmotor Parkinson’s: The Hidden Face - Management and the Hidden Face of Related Disorders. Elsevier; 2017. pp. 947-71. [DOI: 10.1016/bs.irn.2017.05.021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
17 Titova N, Chaudhuri KR. Non-motor Parkinson disease: new concepts and personalised management. Med J Aust 2018;208:404-9. [PMID: 29764353 DOI: 10.5694/mja17.00993] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 13.3] [Reference Citation Analysis]
18 Murai T, Mutoh N. Sequential Addition Reaction of Sulfanylmethyllithiums and Grignard Reagents to Thioformamides Leading to the Formation of 2-Phenyl-2-sulfanylethyl Tertiary Amines. J Org Chem 2016;81:8131-4. [PMID: 27565031 DOI: 10.1021/acs.joc.6b01857] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
19 Mirzaei S, Kulkarni K, Zhou K, Crack PJ, Aguilar MI, Finkelstein DI, Forsythe JS. Biomaterial Strategies for Restorative Therapies in Parkinson's Disease. ACS Chem Neurosci 2021;12:4224-35. [PMID: 34634903 DOI: 10.1021/acschemneuro.1c00484] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
20 Pilipovich AA, Golubev VL. The agonist of dopamine receptors piribedil in treatment of Parkinson’s disease. Z nevrol psikhiatr im S S Korsakova 2017;117:83. [DOI: 10.17116/jnevro20171176183-90] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
21 Dietrichs E, Odin P. Algorithms for the treatment of motor problems in Parkinson's disease. Acta Neurol Scand 2017;136:378-85. [PMID: 28133726 DOI: 10.1111/ane.12733] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
22 Perez-lloret S. Investigational drugs for autonomic dysfunction in Parkinson’s disease. Expert Opinion on Investigational Drugs 2016;25:259-62. [DOI: 10.1517/13543784.2016.1135128] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Watanabe H, Saiki H, Chiu SW, Yamaguchi T, Kashihara K, Tsuboi Y, Nomoto M, Hattori N, Maeda T, Shimo Y; J‐FIRST Group. Real-World Nonmotor Changes in Patients with Parkinson's Disease and Motor Fluctuations: J-FIRST. Mov Disord Clin Pract 2020;7:431-9. [PMID: 32373660 DOI: 10.1002/mdc3.12939] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
24 Perez-Lloret S, Peralta MC, Barrantes FJ. Pharmacotherapies for Parkinson's disease symptoms related to cholinergic degeneration. Expert Opin Pharmacother 2016;17:2405-15. [PMID: 27785919 DOI: 10.1080/14656566.2016.1254189] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
25 Zeeshan F, Mishra DK, Kesharwani P. From the nose to the brain, nanomedicine drug delivery. Theory and Applications of Nonparenteral Nanomedicines. Elsevier; 2021. pp. 153-80. [DOI: 10.1016/b978-0-12-820466-5.00008-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci 2017;18:435-50. [PMID: 28592904 DOI: 10.1038/nrn.2017.62] [Cited by in Crossref: 429] [Cited by in F6Publishing: 407] [Article Influence: 85.8] [Reference Citation Analysis]
27 Flach A, Jaegers L, Krieger M, Bixler E, Kelly P, Weiss EP, Ahmad SO. Endurance exercise improves function in individuals with Parkinson’s disease: A meta-analysis. Neuroscience Letters 2017;659:115-9. [DOI: 10.1016/j.neulet.2017.08.076] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
28 Weiss D, Hieber L, Sturm J, Börtlein A, Buchthal J, Dippon C, Arnold G, Wächter T. Health-related quality of life outcomes from botulinumtoxin treatment in blepharospasm. Clin Neurol Neurosurg 2018;172:130-3. [PMID: 29990961 DOI: 10.1016/j.clineuro.2018.06.040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
29 Chaudhuri KR, Schrag A, Weintraub D, Rizos A, Rodriguez-Blazquez C, Mamikonyan E, Martinez-Martin P. The movement disorder society nonmotor rating scale: Initial validation study. Mov Disord 2020;35:116-33. [PMID: 31571279 DOI: 10.1002/mds.27862] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
30 de Natale ER, Wilson H, Politis M. Serotonergic imaging in Parkinson's disease. Prog Brain Res 2021;261:303-38. [PMID: 33785134 DOI: 10.1016/bs.pbr.2020.11.001] [Reference Citation Analysis]
31 Valera E, Masliah E. Therapeutic approaches in Parkinson's disease and related disorders. J Neurochem 2016;139 Suppl 1:346-52. [PMID: 26749150 DOI: 10.1111/jnc.13529] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
32 Zou S, Lan YL, Hu YP, Yin XX, Liu WL, Li T, Liang Z. Update on the clinical application of deep brain stimulation in sleep dysfunction of Parkinson's disease. Acta Neurol Belg 2018;118:351-9. [PMID: 29987555 DOI: 10.1007/s13760-018-0971-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Ramazzina I, Bernazzoli B, Costantino C. Systematic review on strength training in Parkinson's disease: an unsolved question. Clin Interv Aging 2017;12:619-28. [PMID: 28408811 DOI: 10.2147/CIA.S131903] [Cited by in Crossref: 30] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
34 Teixeira FG, Gago MF, Marques P, Moreira PS, Magalhães R, Sousa N, Salgado AJ. Safinamide: a new hope for Parkinson's disease? Drug Discov Today 2018;23:736-44. [PMID: 29339106 DOI: 10.1016/j.drudis.2018.01.033] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
35 Van der Schyf CJ. Psychotropic Drug Development Strategies that Target Neuropsychiatric Etiologies in Alzheimer's and Parkinson's Diseases: TARGETING NEUROPSYCHIATRIC BURDEN IN AD & PD. Drug Dev Res 2016;77:458-68. [DOI: 10.1002/ddr.21368] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
36 Giorgi FS, Biagioni F, Galgani A, Pavese N, Lazzeri G, Fornai F. Locus Coeruleus Modulates Neuroinflammation in Parkinsonism and Dementia. Int J Mol Sci 2020;21:E8630. [PMID: 33207731 DOI: 10.3390/ijms21228630] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
37 Vijiaratnam N, Foltynie T. Therapeutic Strategies to Treat or Prevent Off Episodes in Adults with Parkinson's Disease. Drugs 2020;80:775-96. [PMID: 32382948 DOI: 10.1007/s40265-020-01310-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
38 Fujita M, Hagino Y, Takamatsu Y, Shimizu Y, Takamatsu Y, Ikeda K, Hashimoto M. Early manifestation of depressive-like behavior in transgenic mice that express dementia with Lewy body-linked mutant β-synuclein. Neuropsychopharmacol Rep 2018;38:95-7. [PMID: 30106256 DOI: 10.1002/npr2.12009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
39 Endepols H, Zlatopolskiy BD, Zischler J, Alavinejad N, Apetz N, Vus S, Drzezga A, Neumaier B. Imaging of cerebral tryptophan metabolism using 7-[18F]FTrp-PET in a unilateral Parkinsonian rat model. Neuroimage 2021;247:118842. [PMID: 34942366 DOI: 10.1016/j.neuroimage.2021.118842] [Reference Citation Analysis]
40 Sid-Otmane L, Huot P, Panisset M. Effect of Antidepressants on Psychotic Symptoms in Parkinson Disease: A Review of Case Reports and Case Series. Clin Neuropharmacol 2020;43:61-5. [PMID: 32217864 DOI: 10.1097/WNF.0000000000000384] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Paul BS, Singh A, Jain D, Singh G, Kaushal S, Paul G, Kaura K. Assessment of fatigue in Parkinson's disease: Indian perspective. Ann Indian Acad Neurol 2016;19:451-5. [PMID: 27994352 DOI: 10.4103/0972-2327.194419] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
42 Stocchi F, Radicati FG, Chaudhuri KR, Johansson A, Padmakumar C, Falup‐pecurariu C, Martinez‐martin P. The Parkinson's Disease Composite Scale: results of the first validation study. Eur J Neurol 2018;25:503-11. [DOI: 10.1111/ene.13529] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
43 Weiss D, Hieber L, Sturm J, Börtlein A, Mayr I, Appy M, Kühnler B, Buchthal J, Dippon C, Arnold G, Wächter T. Botulinumtoxin Improves both Generic and Disease-Specific Quality of Life in Cervical Dystonia. Front Neurol 2017;8:561. [PMID: 29114239 DOI: 10.3389/fneur.2017.00561] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
44 Titova N, Chaudhuri KR. Nonmotor Parkinson's and Future Directions. Int Rev Neurobiol 2017;134:1493-505. [PMID: 28805581 DOI: 10.1016/bs.irn.2017.05.017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
45 Riccardi C, Napolitano F, Montesarchio D, Sampaolo S, Melone MAB. Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases. Pharmaceutics 2021;13:1897. [PMID: 34834311 DOI: 10.3390/pharmaceutics13111897] [Reference Citation Analysis]
46 Barone P, Erro R, Picillo M. Quality of Life and Nonmotor Symptoms in Parkinson's Disease. Int Rev Neurobiol 2017;133:499-516. [PMID: 28802930 DOI: 10.1016/bs.irn.2017.05.023] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
47 Tirassa P, Schirinzi T, Raspa M, Ralli M, Greco A, Polimeni A, Possenti R, Mercuri NB, Severini C. What substance P might tell us about the prognosis and mechanism of Parkinson's disease? Neurosci Biobehav Rev 2021;131:899-911. [PMID: 34653503 DOI: 10.1016/j.neubiorev.2021.10.008] [Reference Citation Analysis]
48 Reynolds GO, Saint-Hilaire M, Thomas CA, Barlow DH, Cronin-Golomb A. Cognitive-Behavioral Therapy for Anxiety in Parkinson's Disease. Behav Modif 2020;44:552-79. [PMID: 30931594 DOI: 10.1177/0145445519838828] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
49 Crowley EK, Nolan YM, Sullivan AM. Exercise as a therapeutic intervention for motor and non-motor symptoms in Parkinson's disease: Evidence from rodent models. Prog Neurobiol 2019;172:2-22. [PMID: 30481560 DOI: 10.1016/j.pneurobio.2018.11.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
50 Perez-Lloret S, Rascol O. Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease. CNS Drugs 2016;30:703-17. [PMID: 27344665 DOI: 10.1007/s40263-016-0360-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
51 Colosimo C, Bhidayasiri R. Nonmotor symptoms in Parkinson's disease: are we still waiting for the honeymoon? Eur J Neurol 2016;23:1595-6. [DOI: 10.1111/ene.13123] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
52 Ghielen I, van Wegen EE, Rutten S, de Goede CJ, Houniet-de Gier M, Collette EH, Burgers-bots IA, Twisk JW, Kwakkel G, Vermunt K, van Vliet B, Berendse HW, van den Heuvel OA. Body awareness training in the treatment of wearing-off related anxiety in patients with Parkinson's disease: Results from a pilot randomized controlled trial. Journal of Psychosomatic Research 2017;103:1-8. [DOI: 10.1016/j.jpsychores.2017.09.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
53 Sauerbier A, Cova I, Rosa-Grilo M, Taddei RN, Mischley LK, Chaudhuri KR. Treatment of Nonmotor Symptoms in Parkinson's Disease. Int Rev Neurobiol 2017;132:361-79. [PMID: 28554415 DOI: 10.1016/bs.irn.2017.03.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
54 Parnetti L, Cicognola C, Eusebi P, Chiasserini D. Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis. Biomark Med 2016;10:35-49. [PMID: 26643452 DOI: 10.2217/bmm.15.107] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
55 Berardelli I, Bloise MC, Bologna M, Conte A, Pompili M, Lamis DA, Pasquini M, Fabbrini G. Cognitive behavioral group therapy versus psychoeducational intervention in Parkinson's disease. Neuropsychiatr Dis Treat 2018;14:399-405. [PMID: 29416341 DOI: 10.2147/NDT.S152221] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 3.8] [Reference Citation Analysis]
56 Peball M, Werkmann M, Ellmerer P, Stolz R, Valent D, Knaus HG, Ulmer H, Djamshidian A, Poewe W, Seppi K. Nabilone for non-motor symptoms of Parkinson's disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study). J Neural Transm (Vienna) 2019;126:1061-72. [PMID: 31129719 DOI: 10.1007/s00702-019-02021-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
57 Yang W, Yu S. Synucleinopathies: common features and hippocampal manifestations. Cell Mol Life Sci 2017;74:1485-501. [DOI: 10.1007/s00018-016-2411-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
58 Moretti R, Caruso P, Dal Ben M. Rivastigmine as a Symptomatic Treatment for Apathy in Parkinson's Dementia Complex: New Aspects for This Riddle. Parkinsons Dis 2017;2017:6219851. [PMID: 28409049 DOI: 10.1155/2017/6219851] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]